<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id>
<journal-id journal-id-type="publisher-id">BPH</journal-id>
<journal-title-group>
<journal-title>British Journal of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1188</issn>
<issn pub-type="epub">1476-5381</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29722028</article-id>
<article-id pub-id-type="pmc">6031880</article-id>
<article-id pub-id-type="doi">10.1111/bph.14345</article-id>
<article-id pub-id-type="publisher-id">BPH14345</article-id>
<article-id pub-id-type="other">2018-BJP-0195-RC.R1</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Emerging disease‐modifying strategies targeting α‐synuclein for the treatment of Parkinson's disease</article-title>
<alt-title alt-title-type="right-running-head">Targeting α‐synuclein for treatment of Parkinson's disease</alt-title>
<alt-title alt-title-type="left-running-head">D M O Hara et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="bph14345-cr-0001">
<name>
<surname>O'Hara</surname>
<given-names>Darren M</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0766-2061</contrib-id>
<xref ref-type="aff" rid="bph14345-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph14345-cr-0002">
<name>
<surname>Kalia</surname>
<given-names>Suneil K</given-names>
</name>
<xref ref-type="aff" rid="bph14345-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph14345-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="bph14345-cr-0003">
<name>
<surname>Kalia</surname>
<given-names>Lorraine V</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9384-1305</contrib-id>
<address>
<email>lorraine.kalia@utoronto.ca</email>
</address>
<xref ref-type="aff" rid="bph14345-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="bph14345-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="bph14345-aff-0004">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="bph14345-aff-0005">
<sup>5</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bph14345-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Krembil Research Institute, Toronto Western Hospital</named-content>
<institution>University Health Network</institution>
<named-content content-type="city">Toronto</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bph14345-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Division of Neurosurgery, Department of Surgery</named-content>
<institution>University of Toronto</institution>
<named-content content-type="city">Toronto</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bph14345-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Division of Neurology, Department of Medicine</named-content>
<institution>University of Toronto</institution>
<named-content content-type="city">Toronto</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bph14345-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital</named-content>
<institution>University Health Network</institution>
<named-content content-type="city">Toronto</named-content>
<country country="CA">Canada</country>
</aff>
<aff id="bph14345-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Tanz Centre for Research in Neurodegenerative Diseases</named-content>
<institution>University of Toronto</institution>
<named-content content-type="city">Toronto</named-content>
<country country="CA">Canada</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Dr Lorraine V Kalia, Toronto Western Hospital, 399 Bathurst Street, McL 7, Toronto, ON M5T 2S8, Canada. E‐mail: <email>lorraine.kalia@utoronto.ca</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2018</year>
</pub-date>
<volume>175</volume>
<issue>15</issue>
<issue-id pub-id-type="doi">10.1111/bph.v175.15</issue-id>
<fpage>3080</fpage>
<lpage>3089</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>4</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BPH-175-3080.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p>Parkinson's disease is the most common neurodegenerative movement disorder. It arises as a result of neuronal cell death in specific brain regions, notably the substantia nigra pars compacta, and is characterized by the accumulation of α‐synuclein in these brain regions. Current pharmacological therapies alleviate the motor symptoms of the disease and are particularly effective in the early stages of the disease. Ongoing drug development efforts focus on disease‐modifying strategies that aim to halt or slow disease progression. In this review, we explore a number of emerging disease‐modifying strategies with a focus on direct and indirect targeting of α‐synuclein dysfunction. We summarize newer classes of small molecules and biological agents intended to attenuate protein aggregation or to target enzymes that may increase the degradation of the pathogenic forms of α‐synuclein. Finally, we discuss emerging strategies that are demonstrating the potential for disease modification at the preclinical stage.</p>
</abstract>
<counts>
<fig-count count="3"></fig-count>
<table-count count="0"></table-count>
<page-count count="10"></page-count>
<word-count count="5673"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bph14345</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>August 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.1.1 mode:remove_FC converted:05.07.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bph14345-cit-0000" publication-type="journal">
<string-name>
<surname>O'Hara</surname>, <given-names>D. M.</given-names>
</string-name>, <string-name>
<surname>Kalia</surname>, <given-names>S. K.</given-names>
</string-name>, and <string-name>
<surname>Kalia</surname>, <given-names>L. V.</given-names>
</string-name> (<year>2018</year>) <article-title>Emerging disease‐modifying strategies targeting α‐synuclein for the treatment of Parkinson's disease</article-title>. <source xml:lang="en"/>British Journal of Pharmacology, <volume>175</volume>: <fpage>3080</fpage>–<lpage>3089</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/bph.14345">https://doi.org/10.1111/bph.14345</ext-link>.</mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>